Page 457 - Binder2

The biologics of the future will save more, last longer, and
earn trust faster—but only if capital learns to see those
attributes as fundamental, not fringe.

The System Must Align on Time

Policy defines what gets approved.
Mindset defines what gets built.
Investment defines what gets funded.

And until all three start valuing time—the time a drug can
stay effective, the time a patient remains stable, the time a
system runs without switching—biologics will continue to
fail by design.

But we have the tools to change that.
We just need the alignment—and the will—to use them.

The Bottom Line: We Must Shift the
Architecture

Science alone won’t fix tolerization. We need new rules,
new norms, and new incentives.

The biologics industry must stop managing around immune
failure and start preventing it. That means aligning:

• Policy that rewards resilience over launch speed
• Mindsets that prioritize cooperation over
suppression
• Capital that understands immune durability as a
strategic moat

455